Likewise, although NGS might have limited prognostic value in HER2-positive and triple-negative cancers as most of these tumors are of high grade (grade 3) [30, 33], these tumors also typically exhibit poor-prognosis gene signatures [45]. In addition, molecular classifiers such as Oncotype DX...
Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. SM,Brown S,Doughty JC,Mallon EA,Cooke TG,Edwards J.Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours... Tovey,M S.,Brown,... - 《British...
Here, we investigated the safety of a new dose scheme for palbociclib, which avoids dose delays or reductions due to afebrile grade 3 neutropenia.MethodsA consecutive cohort of ER( +)/HER2( ) advanced breast cancer patients who received palbociclib between 2017 and 2018 was analyzed. The ...
Kaplan–Meier curves for HER2 status. Survival curves showing cumulative survival differences (end point=breast cancer-specific survival) between patients positive or negative for HER2. P-value represents log-rank testing of the difference in cumulative survival. Full size image Table 2 Subgroup hazard...
Expression of myxovirus resistance A (MxA) Is associated with tumor-infiltrating lymphocytes in human epidermal growth factor receptor 2 (HER2)-positive breast cancers Cancer Res Treat (2017) B. Burkholder et al. Tumor-induced perturbations of cytokines and immune cell networks Biochim Biophys Acta...
Braman, N. et al. Association of peritumoral radiomics with tumor biology and pathologic response to preoperative targeted therapy for HER2 (ERBB2)-positive breast cancer.JAMA Netw. Open2, e192561 (2019). PubMedPubMed CentralGoogle Scholar ...
Targeting HER2-positive breast cancer: advances and future directions. PMID: 36344672Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. PMID: 37279095Trastuzumab Deruxtecan in HER2-Low Breast Cancer. Reply. PMID: 36130006...
Clinicopathological subtypes were defined as: Luminal A, ER and/or PR positive, HER2 negative, HG 1 or 2; Luminal B, ER and/or PR positive, HER2 negative or positive and/or HG 3; triple negative (TN), ER, PR and HER2 negative independent of HG; HER2 positive, ER, PR negative and ...
Investigators Take Stock of New Landscape for Metastatic HER2-Positive Breast Cancer New Strategies Enhance Care in mUC TILs, the Ultimate in Personalized Immunotherapy, Move Closer to Market Next-Generation Endocrine Therapy Moves Forward in Breast Cancer Trial METex14+ NSCLC Armamentarium Welcomes First...
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. PMID: 33480963 Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. PMID: 33946310 ...